NCT02151344View on ClinicalTrials.gov

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Influenza A Virus, H7N9 Subtype
Interventions
BIOLOGICAL

H7N9 A/Anhui/13 ca influenza virus vaccine

Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.

BIOLOGICAL

Inactivated subvirion H7N9 vaccine

Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.

Trial Locations (1)

21205

Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02151344 - Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals | Biotech Hunter | Biotech Hunter